tiprankstipranks
Trending News
More News >

Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials

Story Highlights
  • Psyence BioMed is advancing its position in psychedelic medicine with clinical trials and scalable manufacturing.
  • The company is conducting a Phase IIb trial in Australia and preparing a trial for Alcohol Use Disorder.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials

An announcement from Psyence Biomedical ( (PBM) ) is now available.

Psyence Biomedical Ltd. is advancing its position in the psychedelic medicine industry with a multi-asset strategy, focusing on clinical trials and scalable manufacturing. The company is conducting a Phase IIb clinical trial in Australia for adjustment disorder in cancer patients, leveraging the country’s favorable regulatory environment and tax incentives. This trial, along with strategic partnerships and a strong scientific advisory board, positions Psyence BioMed at the forefront of psychedelic therapeutics. The company is also preparing to launch a clinical trial for Alcohol Use Disorder, addressing significant unmet medical needs. With a strong financial position and strategic growth plans, Psyence BioMed aims to capitalize on the projected growth of the psychedelic mushroom market, enhancing shareholder value and advancing mental health care through psychedelic-assisted therapies.

More about Psyence Biomedical

Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. It is notable for being the first life sciences biotechnology company focused on developing nature-derived psilocybin-based psychedelic medicine to be listed on Nasdaq.

YTD Price Performance: -71.15%

Average Trading Volume: 380,014

Technical Sentiment Signal: Buy

Current Market Cap: $2.34M

For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App